CD28 and neoplasm: Mice were treated with NILK-2301 and NI-3301, two TCEs that target either CD3 (33) or CD28 (32), respectively, and CEA cell adhesion molecule 5 (CEACAM5), and tumor growth and mouse survival were followed for 56 days.